Premier Biomedical, Inc. (OTCQB: BIEI) announced favorable results of initial multi-faceted mouse testing of their patent pending anti-cancer antibody, PBI-5D3H5. The antibody demonstrated superiority against commercially available competitive drugs based on tumor volume and mouse survivability. Read the full press release here:https://upticknewswire.com/premier-biomedical-anti-cancer-antibody-outperforms-leading-multi-billion-dollar-commercial-cancer-treatments-in-initial-head-to-head-testing-at-a-major-university/
Uptick Newswire provided the above as a paid service. It is understood that investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Any suggestions made by Uptick Newswire staff regarding companies featured on upticknewswire.com is solely that “a suggestion” nothing more. It is our expectation that investors will do their own due diligence. We recommend that readers use the information found within as a starting point for conducting their own research on the featured company in order to determine their own personal opinion of the company before investing. Uptick Newswire is not liable for any investment decisions made by our readers. Readers should investigate and fully understand all risks before investing.